Belzutifan: a novel therapy for von Hippel–Lindau disease
A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associa...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Nephrology 2022-04, Vol.18 (4), p.205-206 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 4 |
| container_start_page | 205 |
| container_title | Nature reviews. Nephrology |
| container_volume | 18 |
| creator | Zhou, Jingcheng Gong, Kan |
| description | A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease. |
| doi_str_mv | 10.1038/s41581-022-00544-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626890614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2642273222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-eed8781924fd998464348782ea5ef3028f3c5b987d0d0b56cb501dcd2c7e560d3</originalsourceid><addsrcrecordid>eNp9kEtOwzAQhi0EouVxARYoEhs2Ab_jwAoqoEiV2IDEznLjCaRKk2AnlcqKO3BDToIhpUgsWHnk-ea350PogOATgpk69ZwIRWJMaYyx4DwWG2hIEpHGAiePm-takgHa8X6GsZQ8EdtowARhlBI5ROeXUL52bZGb6iwyUVUvoIzaZ3CmWUZ57aJFXUXjommg_Hh7nxSVNV1kCw_Gwx7ayk3pYX917qKH66v70Tie3N3cji4mccawaGMAqxJFUspzm6aKS854uKBgBOQMU5WzTExTlVhs8VTIbCowsZmlWQJCYst20XGf27j6pQPf6nnhMyhLU0HdeU0llSoNa_KAHv1BZ3XnqvC7QHFKk7A2DRTtqczV3jvIdeOKuXFLTbD-Uqt7tTqo1d9qtQhDh6vobjoHux75cRkA1gM-tKoncL9v_xP7CbGpgvU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642273222</pqid></control><display><type>article</type><title>Belzutifan: a novel therapy for von Hippel–Lindau disease</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Zhou, Jingcheng ; Gong, Kan</creator><creatorcontrib>Zhou, Jingcheng ; Gong, Kan</creatorcontrib><description>A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease.</description><identifier>ISSN: 1759-5061</identifier><identifier>EISSN: 1759-507X</identifier><identifier>DOI: 10.1038/s41581-022-00544-5</identifier><identifier>PMID: 35132216</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67/1059/602 ; 692/4028/67/589/1588/1351 ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Carcinoma, Renal Cell - pathology ; Clinical trials ; Female ; Humans ; Immunotherapy ; Kidney cancer ; Kidney Neoplasms - pathology ; Kinases ; Male ; Medicine ; Medicine & Public Health ; Mutation ; Nephrology ; News & Views ; news-and-views ; Patients ; Proteins ; Quality of life ; Tumors ; Urology ; Vascular endothelial growth factor ; von Hippel-Lindau Disease - complications ; von Hippel-Lindau Disease - drug therapy</subject><ispartof>Nature reviews. Nephrology, 2022-04, Vol.18 (4), p.205-206</ispartof><rights>Springer Nature Limited 2022</rights><rights>Springer Nature Limited 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-eed8781924fd998464348782ea5ef3028f3c5b987d0d0b56cb501dcd2c7e560d3</citedby><cites>FETCH-LOGICAL-c305t-eed8781924fd998464348782ea5ef3028f3c5b987d0d0b56cb501dcd2c7e560d3</cites><orcidid>0000-0001-7195-677X ; 0000-0002-6226-5667</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41581-022-00544-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41581-022-00544-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35132216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Jingcheng</creatorcontrib><creatorcontrib>Gong, Kan</creatorcontrib><title>Belzutifan: a novel therapy for von Hippel–Lindau disease</title><title>Nature reviews. Nephrology</title><addtitle>Nat Rev Nephrol</addtitle><addtitle>Nat Rev Nephrol</addtitle><description>A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease.</description><subject>692/4028/67/1059/602</subject><subject>692/4028/67/589/1588/1351</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Clinical trials</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kinases</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Nephrology</subject><subject>News & Views</subject><subject>news-and-views</subject><subject>Patients</subject><subject>Proteins</subject><subject>Quality of life</subject><subject>Tumors</subject><subject>Urology</subject><subject>Vascular endothelial growth factor</subject><subject>von Hippel-Lindau Disease - complications</subject><subject>von Hippel-Lindau Disease - drug therapy</subject><issn>1759-5061</issn><issn>1759-507X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kEtOwzAQhi0EouVxARYoEhs2Ab_jwAoqoEiV2IDEznLjCaRKk2AnlcqKO3BDToIhpUgsWHnk-ea350PogOATgpk69ZwIRWJMaYyx4DwWG2hIEpHGAiePm-takgHa8X6GsZQ8EdtowARhlBI5ROeXUL52bZGb6iwyUVUvoIzaZ3CmWUZ57aJFXUXjommg_Hh7nxSVNV1kCw_Gwx7ayk3pYX917qKH66v70Tie3N3cji4mccawaGMAqxJFUspzm6aKS854uKBgBOQMU5WzTExTlVhs8VTIbCowsZmlWQJCYst20XGf27j6pQPf6nnhMyhLU0HdeU0llSoNa_KAHv1BZ3XnqvC7QHFKk7A2DRTtqczV3jvIdeOKuXFLTbD-Uqt7tTqo1d9qtQhDh6vobjoHux75cRkA1gM-tKoncL9v_xP7CbGpgvU</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Zhou, Jingcheng</creator><creator>Gong, Kan</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7195-677X</orcidid><orcidid>https://orcid.org/0000-0002-6226-5667</orcidid></search><sort><creationdate>20220401</creationdate><title>Belzutifan: a novel therapy for von Hippel–Lindau disease</title><author>Zhou, Jingcheng ; Gong, Kan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-eed8781924fd998464348782ea5ef3028f3c5b987d0d0b56cb501dcd2c7e560d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>692/4028/67/1059/602</topic><topic>692/4028/67/589/1588/1351</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Clinical trials</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kinases</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Nephrology</topic><topic>News & Views</topic><topic>news-and-views</topic><topic>Patients</topic><topic>Proteins</topic><topic>Quality of life</topic><topic>Tumors</topic><topic>Urology</topic><topic>Vascular endothelial growth factor</topic><topic>von Hippel-Lindau Disease - complications</topic><topic>von Hippel-Lindau Disease - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Jingcheng</creatorcontrib><creatorcontrib>Gong, Kan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Jingcheng</au><au>Gong, Kan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Belzutifan: a novel therapy for von Hippel–Lindau disease</atitle><jtitle>Nature reviews. Nephrology</jtitle><stitle>Nat Rev Nephrol</stitle><addtitle>Nat Rev Nephrol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>18</volume><issue>4</issue><spage>205</spage><epage>206</epage><pages>205-206</pages><issn>1759-5061</issn><eissn>1759-507X</eissn><abstract>A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35132216</pmid><doi>10.1038/s41581-022-00544-5</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-7195-677X</orcidid><orcidid>https://orcid.org/0000-0002-6226-5667</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-5061 |
| ispartof | Nature reviews. Nephrology, 2022-04, Vol.18 (4), p.205-206 |
| issn | 1759-5061 1759-507X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2626890614 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 692/4028/67/1059/602 692/4028/67/589/1588/1351 Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Renal Cell - pathology Clinical trials Female Humans Immunotherapy Kidney cancer Kidney Neoplasms - pathology Kinases Male Medicine Medicine & Public Health Mutation Nephrology News & Views news-and-views Patients Proteins Quality of life Tumors Urology Vascular endothelial growth factor von Hippel-Lindau Disease - complications von Hippel-Lindau Disease - drug therapy |
| title | Belzutifan: a novel therapy for von Hippel–Lindau disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Belzutifan:%20a%20novel%20therapy%20for%20von%20Hippel%E2%80%93Lindau%20disease&rft.jtitle=Nature%20reviews.%20Nephrology&rft.au=Zhou,%20Jingcheng&rft.date=2022-04-01&rft.volume=18&rft.issue=4&rft.spage=205&rft.epage=206&rft.pages=205-206&rft.issn=1759-5061&rft.eissn=1759-507X&rft_id=info:doi/10.1038/s41581-022-00544-5&rft_dat=%3Cproquest_cross%3E2642273222%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642273222&rft_id=info:pmid/35132216&rfr_iscdi=true |